Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomasRaúl M. Luque, Justo P. Castaño, Mônica R. Gadelha et al.|Cancer Letters|2015Cited by 91
A Cellular and Molecular Basis for the Selective Desmopressin-Induced ACTH Release in Cushing Disease Patients: Key Role of AVPR1b Receptor and Potential Therapeutic ImplicationsRaúl M. Luque, Justo P. Castaño, Alfonso Leal‐Cerro et al.|The Journal of Clinical Endocrinology & Metabolism|2013Cited by 81
Octreotide and pasireotide (dis)similarly inhibit pituitary tumor cells in vitroAlejandro Ibáñez‐Costa, Justo P. Castaño, Esther Rivero‐Cortés et al.|Journal of Endocrinology|2016Cited by 74
A Somatostatin Receptor Subtype-3 (SST3) Peptide Agonist Shows Antitumor Effects in Experimental Models of Nonfunctioning Pituitary TumorsMari C. Vázquez‐Borrego, Raúl M. Luque, Gérald Raverot et al.|Clinical Cancer Research|2019Cited by 52
BIM-23A760 influences key functional endpoints in pituitary adenomas and normal pituitaries: molecular mechanisms underlying the differential response in adenomasAlejandro Ibáñez‐Costa, Raúl M. Luque, Laura M. López‐Sánchez et al.|Scientific Reports|2017Cited by 32